All In Biotech

Drug Trial Radar · NCT07672236

A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

A Randomized, Open-label, Phase III Trial to Assess the Efficacy and Safety of BupiZenge Compared to Lidocaine for Pain Associated With Oral Mucositis in Head and Neck Cancer

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 7, 2026

Primary completion

Dec 23, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
OncoZenge ABIndustry
Sponsor type
Industry
Collaborators
Link Medical Research AB
First posted
Jun 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Most patients who receive radiation therapy for head and neck cancer develop painful sores in the mouth called oral mucositis. For many of them, these sores are severe and result in debilitating pain. The sores usually start in the third week of radiation and last aboutfive weeks, often continuing for two weeks after treatment ends. Current pain treatments, for instance lidocaine solution, only give short-lasting pain relief. BupiZenge is a lozenge that dissolves slowly in the mouth and contains bupivacaine. Bupivacaine is a long-acting pain-relieving medicine and has been safely used for many years for both children and adults, and its safety profile is well understood. The BupiZenge lozenge is designed to give longer and more reliable pain relief for patients with mucositis in their mouth. This study will check if BupiZenge works better to reduce pain than lidocaine, and if better pain control improves quality of life and reduces the need for strong pain medicines like opioids. The main goal is to see how much mouth pain decreases after taking BupiZenge compared to lidocaine. This is measured by asking the patients to rate their pain score on a scale from 0 (no pain) to 10 (worst possible pain). This is done at different time-points, from before the dose until three hours after dose on the last day of radiotherapy. The study will include 150 adults, both women and men, aged 18 to 80 years, who have head and neck cancer and are scheduled to receive radiotherapy, with or without chemotherapy. These patients will be randomly assigned to one of the treatment groups. The first is BupiZenge, which is a lozenge containing bupivacaine, which dissolves slowly in the mouth. The second is lidocaine, which is a liquid solution for use in the mouth that you gurgle or swish around in the mouth. The study begins with a combined screening and run-in period that can last up to five weeks. During radiotherapy, patients record their mouth pain each day using a number scale from 0 (no pain) to 10 (worst possible pain). If the pain score is at least 4 (moderate pain) and they have developed mucositis in the mouth within 5 weeks, patients are randomly assigned to receive either BupiZenge or Lidocaine. Treatment continues at least until radiotherapy is completed. If the patient has pain and mouth sores, and the treatment is working well, it may continue after radiotherapy ends, but only until the sores heal or for a maximum of six weeks in total, whichever occurs first. After treatment ends, there is a 30-day follow-up period.

Conditions

  • Head & Neck Cancer
  • Oral Mucositis

Interventions

  • BupiZenge 25 mgDrug

    1 lozenge as needed. Do not chew or swallow. Dosing interval: ≥ 3 h. Max dose/24 h: 8 lozenges.

  • Lidocaine viscous 2%Drug

    10-15 mL as needed. Hold the solution in the mouth and distribute evenly, then either spit out or swallow. Dosing interval ≥ 3 h. Max dose/24 h: 120 mL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total pain reduction in oral cavity pain over 3 hours after taking study treatment on the last day of radiotherapyTime frame: From before to 3 hours after dose, on the last day of radiotherapy

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Rigshospitalet, Copenhagen University Hospital

    Copenhagen, Denmark · Recruiting

  • Herlev Hospital

    Herlev, Denmark · Recruiting

  • Næstved Hospital

    Næstved, Denmark · Recruiting

  • University Hospital Cologne (Universitätsklinikum Köln AöR)

    Cologne, Germany · Not yet recruiting

  • University Hospital Frankfurt (AöR)

    Frankfurt am Main, Germany · Recruiting

  • Medical Center - University Of Freiburg

    Freiburg im Breisgau, Germany · Recruiting

  • University Hospital Schleswig-Holstein (AöR)

    Kiel, Germany · Recruiting

  • University Hospital Tübingen (AöR)

    Tübingen, Germany · Not yet recruiting

  • Helse Bergen HF

    Bergen, Norway · Recruiting

  • Oslo University Hospital HF

    Oslo, Norway · Recruiting

  • Karolinska University Hospital

    Stockholm, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.